Skip to main content
glpverdict
Editorial medical reviewFDA & peer-reviewed sourcesUpdated weeklyMedically reviewed content
HomeGLP-1Which GLP-1 for people with insulin resistance or prediabetes

Evidence review · Drug selection

The best GLP-1 for insulin resistance and prediabetes

Medically reviewed by Jane Novak, MD, MPH, MD, MPH · Endocrinology · Internal Medicine 13 min read Fact checked Editorial integrityUpdated Jul 18, 2026

The honest verdict

For insulin resistance and prediabetes, GLP-1s both drive weight loss and directly improve glycemic control. Tirzepatide (dual GIP/GLP-1) produced the largest HbA1c and weight reductions in trials; semaglutide has extensive diabetes-prevention data. Either substantially reduces progression to type 2 diabetes.

The options, side-by-side

GLP-1 drug options for people with insulin resistance or prediabetes with trial evidence and fit notes.
DrugTrial evidenceFit note
Tirzepatide (Zepbound / Mounjaro)SURPASS: largest HbA1c drop + SURMOUNT-1: −20.9% lossStrongest combined glycemic + weight effect
Semaglutide (Wegovy / Ozempic)SUSTAIN + STEP: strong HbA1c + weight + diabetes preventionExtensive diabetes-prevention evidence
Metformin (comparison, not GLP-1)DPP trial: ~31% diabetes-risk reductionADA first-line for prediabetes; can combine with GLP-1
Liraglutide (Saxenda/Victoza)Older GLP-1Daily injection, lower efficacy — rarely first choice now

Drug selection is a prescriber decision. This table summarizes the trial evidence — it is not a prescription or a substitute for clinical judgment.

Why GLP-1s are well-matched to insulin resistance

Insulin resistance — where cells respond poorly to insulin, driving up blood glucose and insulin levels — is the shared root of prediabetes, type 2 diabetes, PCOS, and much of obesity-related metabolic disease. GLP-1 receptor agonists improve it through two channels: direct glucose-dependent insulin secretion and glucagon suppression, plus the weight loss that itself improves insulin sensitivity.

This dual action is why GLP-1s are so effective here. They were first approved as diabetes drugs (Ozempic, Mounjaro) precisely because of the glycemic effect; the weight-loss indications (Wegovy, Zepbound) came later. For someone with insulin resistance or prediabetes plus excess weight, a GLP-1 addresses both problems with one mechanism.

Tirzepatide leads on glycemic + weight; semaglutide leads on prevention data

In the SURPASS diabetes trial program, tirzepatide produced the largest HbA1c reductions of any GLP-1-class drug, and in SURMOUNT-1 the largest weight loss (−20.9%). Its dual GIP + GLP-1 agonism drives both. For someone whose priority is maximum glycemic and weight improvement, tirzepatide has the strongest data.

Semaglutide has the broader diabetes-prevention evidence base — the SUSTAIN (diabetes) and STEP (obesity) programs together document substantial reductions in progression from prediabetes to type 2 diabetes. For a prediabetic patient whose main goal is not developing diabetes, semaglutide's prevention track record is compelling and its coverage is wider.

Both are excellent choices. The decision often comes down to coverage, tolerability, and whether maximum glycemic control (favors tirzepatide) or the longest prevention track record (favors semaglutide) is the priority.

Where metformin fits

The American Diabetes Association still lists metformin as first-line pharmacotherapy for prediabetes, backed by the landmark Diabetes Prevention Program trial (~31% reduction in progression to type 2 diabetes). It is inexpensive, well-tolerated by most, and has decades of safety data.

A GLP-1 is often added to, or chosen over, metformin when weight loss is also an explicit goal — GLP-1s drive far more weight loss than metformin. The two can be combined under prescriber guidance. For a prediabetic patient with significant excess weight, a GLP-1 (with or without metformin) is a reasonable evidence-based path.

The numbers: what glycemic improvement to expect

Concrete expectations help you judge whether treatment is working. In the diabetes trials, semaglutide lowered HbA1c by roughly 1.5-1.8 percentage points and tirzepatide by up to ~2.0-2.4 points at the highest doses — larger reductions than any prior injectable class. For someone in the prediabetic range (HbA1c 5.7-6.4%), that magnitude of effect commonly returns HbA1c to the normal range (<5.7%).

Fasting glucose and insulin sensitivity improve early — often within the first 4-8 weeks, before large weight loss — because the glycemic effect is partly direct (glucose-dependent insulin secretion and glucagon suppression), not solely weight-mediated. If you monitor at home, expect fasting glucose to trend down first, then post-meal spikes to flatten as the dose escalates.

Hypoglycemia and combining with other diabetes drugs

GLP-1s alone rarely cause hypoglycemia because their insulin-stimulating effect is glucose-dependent — it switches off as glucose normalizes. The risk appears when a GLP-1 is combined with insulin or a sulfonylurea (glipizide, glimepiride), where the added insulin effect can drive glucose too low. If you take either, your prescriber will typically reduce those doses when starting a GLP-1.

This is a managed adjustment, not a reason to avoid the combination. For an insulin-resistant or prediabetic patient not on insulin or a sulfonylurea, hypoglycemia risk from a GLP-1 is low. Anyone monitoring glucose should still know the symptoms (shakiness, sweating, confusion) and how to treat a low.

Dosing, side effects, and cost

Dosing follows the standard escalation (Wegovy 0.25→2.4 mg; Zepbound 2.5→up to 15 mg, each step ~4 weeks). For the glycemic indication specifically, the diabetes-labeled versions (Ozempic, Mounjaro) top out at slightly lower doses than the obesity-labeled versions (Wegovy, Zepbound), which is one reason drug + indication + coverage interact.

Side effects are the standard GI profile, managed with slow titration. On cost: if you have type 2 diabetes, coverage is usually much easier (the diabetes indication is broadly covered) than for prediabetes or insulin resistance alone, where the BMI ≥27-with-comorbidity weight pathway is the common route. If uninsured or denied, manufacturer cash ($349-499/mo) or licensed compounded telehealth ($99-249/mo) are the fallbacks — see the full cost-lowering menu.

How to talk to your prescriber

Bring recent labs (HbA1c, fasting glucose, and if available a fasting insulin or a calculated HOMA-IR), your family history of diabetes, and your current medication list. If you already take metformin, insulin, or a sulfonylurea, flag it — it changes both the drug choice and the dose-adjustment plan.

Useful questions: "Does my insulin resistance qualify me for coverage, or do I need a diabetes diagnosis?" "Should I add this to metformin or replace it?" "What HbA1c or glucose target are we aiming for?" "How will we adjust my other diabetes meds?" A prescriber who manages metabolic disease will welcome the specificity.

Frequently asked

Which GLP-1 is best for insulin resistance?

Tirzepatide (Zepbound/Mounjaro) produced the largest HbA1c and weight reductions in trials, making it the strongest combined glycemic-and-weight choice. Semaglutide has broader diabetes-prevention evidence and wider coverage. Both substantially improve insulin resistance; the decision is individualized.

Can a GLP-1 reverse prediabetes?

GLP-1s substantially reduce progression from prediabetes to type 2 diabetes and can return HbA1c to the normal range in many patients — through both direct glycemic effects and weight loss. Whether this counts as "reversal" depends on definitions, but the risk reduction is real and well-documented.

Do I qualify for a GLP-1 with prediabetes but not diabetes?

Often, yes — via the weight indication. Prediabetes itself is not an FDA weight-loss indication, but BMI ≥27 with a weight-related comorbidity (which insulin resistance/prediabetes can support) is the common qualifying path. Your prescriber makes the determination.

Should I take metformin or a GLP-1 for insulin resistance?

Metformin is ADA first-line for prediabetes and is inexpensive with decades of safety data. A GLP-1 drives far more weight loss and greater glycemic improvement but costs more. Many patients use both. If weight loss is a major goal, a GLP-1 (with or without metformin) is reasonable.

Next steps

Other situations

Your situation may span more than one of these. Each guide reads the trial evidence for a different starting point.

Sources

This page describes published evidence and is not medical advice. GLP-1 drug selection is a decision for a licensed prescriber who has assessed you individually.

Best GLP-1 for Insulin Resistance / Prediabetes 2026 — Evidence Review